$Rho-Kinase Inhibitors for the Treatment of Refractory Diabetic Macular Oedema$

Rho-Kinase Inhibitors for the Treatment of Refractory Diabetic Macular Oedema

Diabetic macular oedema (DMO) is one of the leading causes of vision loss associated with diabetic retinopathy (DR). New insights in managing this condition have changed the paradigm in its treatment, with intravitreal injections of antivascular endothelial growth factor (anti-VEGF) having become th...

Full description

Bibliographic Details
Main Authors:	Milagros Mateos-Olivares, Luis García-Onrubia, Fco. Javier Valentín-Bravo, Rogelio González-Sarmiento, Maribel Lopez-Galvez, J. Carlos Pastor, Ricardo Usategui-Martín, Salvador Pastor-Idoate
Format:	Article
Language:	English
Published:	MDPI AG 2021-07-01
Series:	Cells
Subjects:	diabetic macular oedema diabetic retinopathy macular oedema rho-associated kinases
Online Access:	https://www.mdpi.com/2073-4409/10/7/1683

Similar Items

Macular oedema after uncomplicated phacoemulsification
by: Aymen D. Jaafar, et al.
Published: (2022-06-01)

Concentrated triamcinolone acetonide suprachoroidally administered for the treatment of diabetic macular oedema
by: Petrović Nenad, et al.
Published: (2023-01-01)

Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Oedema: Lessons Learned from Registration Trials
by: Helene O. Larsen, et al.
Published: (2023-07-01)

Quantitative Assessment of Choroidal Parameters in Patients with Various Types of Diabetic Macular Oedema: A Single-Centre Cross-Sectional Analysis
by: Diana Anna Dmuchowska, et al.
Published: (2021-07-01)

Study of aqueous humour inflammatory mediators’ levels in a cohort of Egyptian patients with diabetic macular oedema
by: Amir Ramadan Gomaa, et al.
Published: (2023-11-01)

Clinical Effectiveness of Intravitreal Fluocinolone Acetonide (FAc) (ILUVIEN™) in Patients with Diabetic Macular Oedema (DMO) Refractory to Prior Therapy: The Manchester Experience
by: James F. Young, et al.
Published: (2019-07-01)

Indicators of Visual Prognosis in Diabetic Macular Oedema
by: Sagnik Sen, et al.
Published: (2021-05-01)

Accidental intralenticular injection of dexametasone intravitreal implant during the treatment of refractory diabetic macular oedema
by: M. I. Kovtun, et al.
Published: (2018-04-01)

Intravitreal Fluocinolone Acetonide (ILUVIEN) Implant for the Treatment of Refractory Cystoid Macular Oedema After Retinal Detachment Repair
by: Fadi Alfaqawi, et al.
Published: (2018-06-01)

Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years
by: William Fusi-Rubiano, et al.
Published: (2018-02-01)

Chronic Macular Oedema as a Late MIRAgel-Related Complication
by: Chung Shen Chean, et al.
Published: (2021-11-01)

Detection of diabetic macular oedema: validation of optical coherence tomography using both foveal thickness and intraretinal fluid
by: Carmen Hernández-Martínez, et al.
Published: (2015-11-01)

Incidence of Pseudophakic Cystoid Macular Oedema Post-Cataract Surgery in Illawarra Shoalhaven Local Health District, Australia
by: Ishith Seth, et al.
Published: (2022-01-01)

Real Life Experience of Dexamethasone Implant in Refractory Diabetic Macular Oedema
by: Karttunen T, et al.
Published: (2019-12-01)

Fluocinolone Acetonide Implant Injected 1 Month after Dexamethasone Implant for Diabetic Macular Oedema: the ILUVI1MOIS Study
by: Nicolas Rousseau, et al.
Published: (2023-06-01)

Clinical effects and safety of treating diabetic macular edema with intravitreal injection of ranibizumab combined with retinal photocoagulation
by: Yan PS, et al.
Published: (2016-04-01)

Burden Of Treatment Among Patients Undergoing Intravitreal Injections For Diabetic Macular Oedema In Australia
by: Spooner KL, et al.
Published: (2019-09-01)

Influence of glycaemic control on macular thickness in diabetic retinopathy
by: Sadhana Sharma, et al.
Published: (2022-01-01)

Diversity when interpreting evidence in network meta-analyses (NMAs) on similar topics: an example case of NMAs on diabetic macular oedema
by: Jing Wu, et al.
Published: (2023-10-01)

Intravitreal Dexamethasone Implant (IDI) Alone and Combined with Navigated 577 nm Subthreshold Micropulse Laser (SML) for Diabetic Macular Oedema
by: Lisa Toto, et al.
Published: (2022-09-01)

Intravitreal dexamethasone implant therapy for the treatment of cystoid macular Oedema due to hydroxychloroquine retinopathy: a case report and literature review
by: Seong Joon Ahn, et al.
Published: (2018-12-01)

Modern diagnostic and treatment aspects of diabetic macular edema
by: Alexander Viktorovich Doga, et al.
Published: (2014-12-01)

Treatment of Retinitis Pigmentosa-Associated Cystoid Macular Oedema Using Intravitreal Aflibercept (Eylea) despite Minimal Response to Ranibizumab (Lucentis): A Case Report
by: Stacey A. Strong, et al.
Published: (2016-09-01)

Cytokine and Chemokine Profile Changes in Patients After Intravitreal Conbercept Injection for Diabetic Macular Edema
by: Wei Q, et al.
Published: (2019-12-01)

Comparison of Ranibizumab alone versus Ranibizumab with Targeted Retinal Laser for Branch Retinal Vein Occlusion with Macular Oedema.
by: Mohamed Abdelmoneem, et al.
Published: (2022-10-01)

CMV retinitis and subsequent acute cystoid macular oedema after treatment with vitreous ganciclovir injection: a case report
by: Mengyun Liu, et al.
Published: (2022-06-01)

External validation of cut-off points for foveal thickness taking into account the intraretinal fluid using optical coherence tomography to diagnose diabetic macular oedema
by: Carmen Hernández-Martínez, et al.
Published: (2017-10-01)

Real-World Outcomes of Anti-VEGF Therapy in Diabetic Macular Oedema: Barriers to Treatment Success and Implications for Low/Lower-Middle-Income Countries
by: Olapeju A. Sam-Oyerinde, et al.
Published: (2023-02-01)

Pathogenesis and Treatment of Refractory Oedema in Nephrotic Syndrome
by: Priyanka Jethwani, et al.
Published: (2021-08-01)

Outcomes of three intravitreal injections of bevacizumab given monthly for diabetic macular oedema is a viable treatment for an economically disadvantaged population
by: Aazambir S. Brar, et al.
Published: (2021-04-01)

Ganglion cell complex changes with long-standing diabetic macular oedema among Egyptian diabetic patients: an optical coherence tomography study
by: Tamer A Refai, et al.
Published: (2018-01-01)

Local Treatment with Triamcinolone Acetonide and Bevacizumab for Ocular Symptoms in a Patient with POEMS Syndrome
by: Marcin G. Prost, et al.
Published: (2014-12-01)

Optical Coherence Tomography Angiography as a Diagnostic Tool for Diabetic Retinopathy
by: Naomi Wijesingha, et al.
Published: (2024-02-01)

Diabetic macular oedema and diode subthreshold micropulse laser (DIAMONDS): study protocol for a randomised controlled trial
by: Noemi Lois, et al.
Published: (2019-02-01)

Bevacizumab therapy for macular edema in central retinal vein occlusion: Long-term results
by: George J Manayath, et al.
Published: (2009-01-01)

Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies
by: Michal Pochopien, et al.
Published: (2019-01-01)

Cerebral Oedema in Diabetic Ketoacidosis
by: Nona Gîrlescu, et al.
Published: (2020-03-01)

Current approaches to the management of diabetic retinopathy
by: Tatiana Yul'evna Demidova, et al.
Published: (2014-10-01)

Early Visual Functional Outcomes and Morphological Responses to Anti-Vascular Growth Factor Therapy in Diabetic Macular Oedema Using Optical Coherence Tomography Angiography
by: Dabir S, et al.
Published: (2021-01-01)

Caracterización de la retinopatía diabética en un programa de tamización en Medellín, Colombia, en el año 2018
by: José P. Vivas-Giraldo, et al.
Published: (2021-07-01)